TOPIC: One Lot of Vancomycin Hydrochloride Injection, USP 1.5g/vial by Hospira: Recall – Due to The Presence of Visible Glass Particulates
AUDIENCE: Health Professional, Infectious Disease, Pharmacy
ISSUE: Hospira, a Pfizer company, is recalling one lot of Vancomycin Hydrochloride Injection, USP, 1.5 g/vial Single Dose Fliptop Vial, lot 33045BA, to the user level due to two visible glass particulates observed in a single vial.
If administered intravenously, patients may experience adverse events such as local irritation or swelling, vasculitis/ phlebitis, antigenic or allergic reactions, and microvascular obstruction, including pulmonary embolism. If administered orally or via a nasogastric tube, there may be the potential for gastrointestinal trauma.
To date, Pfizer has not received reports of any adverse events related to this recall.
For more information about this recall/alert, click on the red button “Read Recall” below.
BACKGROUND: Vancomycin Hydrochloride is an antibiotic indicated for the treatment of serious or severe infections caused by susceptible strains of methicillin-resistant staphylococci. Vancomycin Hydrochloride is effective in the treatment of staphylococcal endocarditis, septicemia, bone infections, lower respiratory tract infections, and skin and skin-structure infections. It is used in penicillin-allergic patients, and also for patients who cannot receive or who have failed to respond to other antimicrobials, including penicillin or cephalosporin agents, and for infections caused by vancomycin-susceptible organisms that are resistant to other antimicrobials.
RECOMMENDATIONS:
|
